Quantcast
Last updated on April 18, 2014 at 5:48 EDT

Latest Caphosol Stories

2013-03-27 08:31:27

PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase 2,...

2012-10-30 12:33:09

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston. MULTIMEDIA ALERT: A video interview with Dr. Miller is available for journalists to download on the Mayo Clinic News Network. "Oral mucositis or mouth sores is a painful and...

2012-06-28 02:28:08

DALLAS and NEW YORK, June 28, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.(OTCBB: ACCP), a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City. The presentation summarized data...

2012-01-26 11:49:27

Slight temperature increases of the oral mucus membranes early in a head and neck cancer patient's chemotherapy and radiation therapy (chemoradiotherapy) treatment is a predictor of severe mucositis later in treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Mucositis, or mouth sores, is a common side effect of chemoradiotherapy for head and neck cancer that is painful and can be very severe. Physicians...

2011-12-07 07:30:00

DALLAS and NEW YORK, Dec. 7, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that an oncology supportive care nurse, Michelle Devries, was interviewed this week on the WWSB-ABC Tampa News at Noon segment covering the common side effects of cancer treatments, specifically oral mucositis, and...

2011-10-14 07:30:00

DALLAS and NEW YORK, Oct. 14, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has updated its MuGard website to include a clinical feedback video. The video features a late-stage colorectal patient and seasoned oncology nurse practitioner's experience with oral mucositis and MuGard. The video also features clips...

2011-10-13 07:30:00

DALLAS and NEW YORK, Oct. 13, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the reimbursement for its lead product for oral mucositis, MuGard, has increased significantly over the past few months. Over the past few months, Access has more than doubled the amount of payers providing coverage for...

2011-09-28 07:30:00

DALLAS and NEW YORK, Sept. 28, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced the findings of an independent presentation on MuGard clinical experience at the 2011 European Multidisciplinary Cancer Congress held in Stockholm, Sweden. The ongoing research study was conducted by the Oncology and...

2011-08-09 07:30:00

DALLAS and NEW YORK, Aug. 9, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Community Specialty Pharmacy Network (CSPN), the 10th-largest network of specialty pharmacies in the U.S., has joined its specialty pharmacy network for MuGard, its lead product for oral mucositis. With more than 180 member...

2011-07-28 07:15:00

DALLAS and NEW YORK, July 28, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has launched its patient reimbursement and support center for its lead product for oral mucositis, MuGard. Referred to as a HUB, the MuGard Patient Reimbursement and Support Center (MuGard PRSC) operated by eMax Health provides a...